The below dates pertain to the Expression of Interest. Following review of the Expressions of Interest, full Research Funding Applications will be solicited by the Centre of Excellence.
Ketamine is an NMDA antagonist and dissociative anesthetic/analgesic currently being used in applications for both chronic pain and mental health. Ketamine is offered in some interdisciplinary chronic pain management clinics across Canada, but there remain some uncertainties about the most appropriate patient populations, modes of delivery, and dosing for optimal effect.
As anecdotal reports grow about the use of Ketamine for treatment resistant mood disorders and its use for chronic pain states (which may also occur concurrently with mood disorders), there is a need to establish the current state of evidence supporting its use. There is also a need to provide appropriate guidance for insurers and other health care funders in supporting its use. This research project is aimed at studying the effectiveness of Ketamine for Veterans managing chronic pain and mental health conditions. This will be a one-year research project.
The total funding available for this one-year research project is $120,000 CAD.
All Expressions of Interest are adjudicated by the Centre of Excellence. Please review our Research Proposal Rating Scale here. All applicants will be notified of the results of the adjudication. Successful applicants will be asked to submit a Research Funding Application. Applicants who are not successful will be withdrawn from the competition.
Click here to view our Funding Guidelines, which provide further information on application, review, results, funding, integrity, and Sex and Gender-Based Analysis Plus (SGBA)+. All applicants are expected to read these guidelines thoroughly before applying. Applications that do not adhere to these guidelines will not be considered.